In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe-Reference-Cited by-同舟云学术

In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe

Published:2020-10-20 Issue:11 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Carvalhaes Cecilia G.¹,Duncan Leonard R.¹,Wang Wen²,Sader Helio S.¹^ORCID

Affiliation:

1. JMI Laboratories, North Liberty, Iowa, USA

2. MicuRx Pharmaceuticals, Inc., Foster City, California, USA

Abstract

Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates ( n = 1,211). Contezolid demonstrated potent activity against Staphylococcus aureus (MIC 50/90 , 0.5/1 mg/liter), coagulase-negative Staphylococcus (MIC 50/90 , 0.25/0.5 mg/liter), Enterococcus spp.

Funder

MicuRx

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01195-20

Reference26 articles.

1. Antibiotic resistance threats in the United States, 2019

2. Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997–2016)

3. Disease Manifestations and Pathogenic Mechanisms of Group A Streptococcus